⏳ Fetching live dividend data...
Home › Calculator › CYCCP Dividend Calculator 2026
Cyclacel Pharmaceuticals, Inc. · NASDAQ
Price: $5.05 · Annual div: $0.60/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CYCCP → $11.2K in 10 years · $0.11/month
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compound is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CYCCP position with:
Real after-tax yield depends on where you live and how you hold CYCCP.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 11.88% | 9.08% | $1,188 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 10.10% | 7.30% | $1,010 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 9.50% | 6.70% | $950 / yr |
| 🇬🇧 UK ISA | 0% | 11.88% | 9.08% | $1,188 / yr |
| 🇬🇧 UK Taxable | 8.75% | 10.84% | 8.04% | $1,084 / yr |
| 🇨🇦 TFSA | 0% | 11.88% | 9.08% | $1,188 / yr |
| 🇨🇦 CA Taxable | 25% | 8.91% | 6.11% | $891 / yr |
| 🇦🇺 Super (pension) | 15% | 10.10% | 7.30% | $1,010 / yr |
| 🇦🇺 AU Taxable | 30% | 8.32% | 5.52% | $832 / yr |
| 🇩🇪 DE Taxable | 26.375% | 8.75% | 5.95% | $875 / yr |
| 🇫🇷 FR Taxable | 30% | 8.32% | 5.52% | $832 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.60/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CYCCP pays quarterly — 4 times per year. Next ex-div: TBD.
How CYCCP compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CYCCP sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2025-11-12 | 200,000 | $1.40 | $280.0K | ||
| A-Award | 2025-11-12 | 300,178 | $1.40 | $420.2K | ||
| J-Other | 2025-11-05 | 467,535 | — | — | ||
| J-Other | 2025-11-05 | 218,000 | $7.65 | $1.67M | ||
| J-Other | 2025-11-05 | 218,000 | $9.00 | $1.96M | ||
| J-Other | 2025-11-05 | 31,535 | $10.20 | $321.7K | ||
| Sale | 2025-11-05 | 28,540 | $1.70 | $48.5K | ||
| J-Other | 2025-11-05 | 467,535 | — | — | ||
| J-Other | 2025-11-05 | 467,535 | — | — | ||
| J-Other | 2025-11-05 | 218,000 | $9.00 | $1.96M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CYCCP dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Cyclacel Pharmaceuticals, Inc. (CYCCP) is currently trading at $5.05, 75% below its 52-week high. The current dividend yield is 11.88% based on an annual payout of $0.60 per share.
Cyclacel Pharmaceuticals, Inc. (CYCCP) is a healthcare stock currently trading at $5.05 with a dividend yield of 11.88%. The company pays an annual dividend of $0.60 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, CYCCP has grown its dividend at a compound annual rate of 50.0%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever